My­ovant shows dis­ap­point­ing prostate can­cer da­ta on the way to the FDA, stock sinks

My­ovant $MY­OV has been prep­ping re­l­u­golix for ad­vanced prostate can­cer over the last sev­er­al months, look­ing to im­prove up­on the old stan­dard in Ab­b­Vie’s Lupron. But new da­ta out Tues­day will not help its cause.

Re­l­u­golix failed to meet a crit­i­cal sec­ondary end­point in a Phase III tri­al and did not achieve sta­tis­ti­cal su­pe­ri­or­i­ty for cas­tra­tion re­sis­tance-free sur­vival af­ter 48 weeks com­pared to the Ab­b­Vie drug. In the sub­group of men with metasta­t­ic prostate can­cer, 74% of those treat­ed with re­l­u­golix were alive and cas­tra­tion-re­sis­tance free through 48 weeks com­pared to 75% on Lupron. The p-val­ue of the study was 0.84.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER